Project Details
Description
This is a randomized study, where each patient will be assigned to receive either MST-188
(the study drug) or a placebo. The study drug or placebo will be administered intravenously, directly into the vein, for up to 49 hours (about 2 days).
About 388 children with sickle cell disease in vaso-occlusive pain crisis will be enrolled in this research study from 70 centers in the Americas, Europe, and the Middle East.
Status | Finished |
---|---|
Effective start/end date | 1/1/14 → 12/31/16 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.